Reply to: Benefit of Helicobacter pylori eradication therapy in all systemic sclerosis patients regardless of clinical symptoms

Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):153. Epub 2019 Oct 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents
  • Drug Therapy, Combination
  • Helicobacter pylori*
  • Humans
  • Scleroderma, Systemic*

Substances

  • Anti-Bacterial Agents